Table 1.

Description of the 15 studies of association between polymorphisms and response to anti‐TNF treatment

Disease	Ethnicity/Country	Treatment Drug(s)	Response criteria based on	Response time	N cases	References
CD	Multicentera	Infliximab	CDAIb	2 weeks	90 + 444	Mascheretti et al.27
CD	Belgium	Infliximab	CDAIb or fistulac	4 and 10 weeks	245	Vermeire et al.38
CD	Belgium	Infliximab	CDAIb or fistula numberc	4 weeks	226	Louis et al.28
CD	Multicentera	Infliximab	CDAIb	4 weeks	90 + 444	Mascheretti et al.26
CD	Belgium	Infliximab	CDAIb, fistulad, or CRPe, CRPf	4 weeks	145	Louis et al.29
CD	Belgium	Infliximab	CDAIb or CRPg	4 and 8 weeks	166	Pierik et al.30
CD	Belgium	Infliximab	CDAIb or fistulad or CRPh	4 and 10 weeks	204	Hlavaty et al.39
CD	Belgium	Infliximab	CDAIb , i, fistulad, or CRPe,f	10 weeks	189	Willot et al.31
CD	Caucasian	Infliximab	CDAIb or fistulac or CRPk	12 weeks	150	Dideberg et al.32
CD	Caucasian	Infliximab	CDAIb, fistulad, CRPf,j	4 and 10 weeks	222	Dideberg et al.33
CD	95.3% Caucasian	Infliximab	CDAIb,i or fistulac or CRPe,f	2 and 6 weeks	344/156	Louis et al.34
CD	Japan	Infliximab	CDAIi, CRPf	4, 8 and 30 weeks	102	Moroi et al.35
CD	Caucasian (Spanish)	Infliximab	HBIk, fistulad	10 weeks	297	Medrano et al.36
CD	Denmark	Infliximab/Adalimumab	SCTSSl	Within 22 weeks	482	Bank et al.25
CD	Slovenian	Adalimumab	IBDQm, CRPh	4, 12, 20 and 30 weeks	102	Koder et al.37
UC	Denmark	Infliximab/Adalimumab	SCTSSl	Within 22 weeks	256	Bank et al.25

^aGerman (cohort I), North America, Europe, Canada, Israel (cohort II).

^bCrohn's disease activity index (CDAI); Clinical response (remission): CDAI below 150, partial response (response): drop of at least 70 CDAI points.

^cFistula number: Complete response (remission): at least 50% reduction in number of fistulae from baseline at two consecutive visits.

^dFistula number: Complete response (remission): complete fistula closure, partial response: at least 50% reduction in number of fistulae from baseline at two consecutive visits.

^eC‐reactive Protein (CRP); Biological response: drop in CRP to normal values (<3 mg/L), partial response: drop in CRP level of more than 25%.

^fCRP, decrease in CRP, absolute and/or relative values, among entire cohort or subgroup having elevated CRP concentrations.

^gCRP; Biological remission were defined as a normalisation (<3 mg/L) and biological response was defined as a >12 mg/L decrease (the mean decrease in CRP) of CRP.

^hC‐reactive protein (CRP); Biological response: drop in CRP to normal values (<3 mg/L) or drop in CRP level of more than 25%.

ⁱCDAI, decrease in CDAI, absolute and/or relative.

^jCRP; Response was defined as a drop in CRP level of more than 25% among patients with an elevated CRP before treatment (more than twice the upper limit of the normal range).

^kHarvey–Bradshaw index (HBI); Clinical response (remission): a final HBI lower than 4 and absence of concomitant corticosteroids, partial response (response): a decreased in HBI by more than 3 points and absence of concomitant corticosteroids.

^lSimple Clinical Three Step Scale (SCTSS); Response: absence or near absence of all clinical symptoms without increase in corticosteroids, Partial response: improvement or tapering of corticosteroids without worsening, nonresponse: No change or worsening of symptoms.

^mIBD questionnaire (IBDQ); Clinical response was defined as an increase in IBDQ of at least 22 or an IBDQ of at least 170.